Market Place
Sourcing Support
Regeneron Highlights Blood Cancer Pipeline at ASH
13 Nov 2024 //
GLOBENEWSWIRE
Regeneron Announces Investor Conference Presentations
11 Nov 2024 //
GLOBENEWSWIRE
Regeneron Reports Q3 2024 Financial and Operating Results
31 Oct 2024 //
GLOBENEWSWIRE
Regeneron`s Biologic Inmazeb Receives Suppl Approval in US
24 Oct 2024 //
FDA
Dupixent® Late-Breaking Phase 3 Data In Chronic Urticaria
24 Oct 2024 //
GLOBENEWSWIRE
Amgen gears up to launch Eylea biosim as Regeneron plots appeal
23 Oct 2024 //
FIERCE PHARMA
EYLEA HD® Injection Shows Gains In Diabetic Macular Edema.
18 Oct 2024 //
GLOBENEWSWIRE
Regeneron and Sanofi’s Dupixent to Dominate COPD Biologics Market
15 Oct 2024 //
BIOSPACE
Regeneron`s Biologic Eylea HD (Aflibercept) Receives Suppl Approval in US
10 Oct 2024 //
FDA
Regeneron Pharma`s Biologic Eylea Receives Suppl Approval in US
10 Oct 2024 //
FDA
Clearside`s CLS-AX excels in phase 2b trial, set for phase 3
10 Oct 2024 //
FIERCE PHARMA
Dupixent takes pharma DTC top spot in September
07 Oct 2024 //
FIERCE PHARMA
Sanofi and Regeneron’s Dupixent Snags First Biologic Approval in COPD
28 Sep 2024 //
BIOSPACE
Dupixent Approved As First Biologic Medicine For COPD Patients
27 Sep 2024 //
GLOBENEWSWIRE
Regeneron To Report Third Quarter 2024 Financial Results
26 Sep 2024 //
GLOBENEWSWIRE
Regeneron loses bid to block Amgen`s Eylea biosim, sinking shares
24 Sep 2024 //
FIERCE PHARMA
Amgen gets early win in Regeneron lawsuit over Eylea biosimilar
23 Sep 2024 //
REUTERS
Dupixent Approved For Adolescents With Chronic Rhinosinusitis With Polyps
13 Sep 2024 //
GLOBENEWSWIRE
Demy-Colton`s BioFuture 2024 To Feature Regeneron, IBM, Ipsen, And VCs
11 Sep 2024 //
BUSINESSWIRE
Dupixent Phase 3 Trial Shows Improvement In Chronic Spontaneous Urticaria
11 Sep 2024 //
GLOBENEWSWIRE
EYLEA HD Data At EURETINA Shows Long-term Durability And Safety
11 Sep 2024 //
GLOBENEWSWIRE
Sanofi And Regeneron Show Data For Dupixent In Hives After FDA Rejection
11 Sep 2024 //
FIERCE PHARMA
Regeneron To Highlight Progress At WCLC And ESMO
09 Sep 2024 //
GLOBENEWSWIRE
Libtayo Demonstrates Durable Survival Benefit In Lung Cancer
09 Sep 2024 //
GLOBENEWSWIRE
Sonoma Biotherapeutics Receives $45M Regeneron Milestone
04 Sep 2024 //
CONTRACT PHARMA
ArsenalBio Snags Mega $325M Series C Round With Backing from Nvidia, Regeneron
04 Sep 2024 //
BIOSPACE
Eyes, Ears Get Their Due With Cell and Gene Therapy
03 Sep 2024 //
BIOSPACE
Regeneron takes on Sandoz over newly-approved Eylea copycat
29 Aug 2024 //
BLOOMBERG
Regeneron Gains European Nod For T-Cell Engager Odronextamab
27 Aug 2024 //
FIERCE PHARMA
Dupixent And Itepekimab Data At ERS Show Leadership In Respiratory Diseases
26 Aug 2024 //
GLOBENEWSWIRE
US FDA declines to approve Regeneron`s blood cancer therapy
21 Aug 2024 //
REUTERS
Regeneron Provides Update on Biologics License Application for Linvoseltamab
20 Aug 2024 //
GLOBENEWSWIRE
Regeneron Announces Investor Presentations And Oncology Webcast
07 Aug 2024 //
GLOBENEWSWIRE
Regeneron Reports Second Quarter 2024 Financial and Operating Results
01 Aug 2024 //
GLOBENEWSWIRE
Regeneron Launches Eylea HD, Warns Of Linvoseltamab Manufacturing Issue
01 Aug 2024 //
FIERCE PHARMA
Regeneron Announces 2024 Prize For Creative Innovation Winners
31 Jul 2024 //
GLOBENEWSWIRE
BioNTech, Regeneron`s mRNA Cancer Candidate Wins In Phase 2 Trial
30 Jul 2024 //
FIERCE BIOTECH
Roche`s Vabysmo Climbs Despite Slowdown Amid Eylea Clash
25 Jul 2024 //
FIERCE PHARMA
Sanofi lifts 2024 profit forecast on strength in Dupixent, new products
25 Jul 2024 //
REUTERS
Court weighs what US must prove in Regeneron kickback case
23 Jul 2024 //
REUTERS
Docs embrace Takeda’s Eohilia, creating competition for Sanofi`s Dupixent
22 Jul 2024 //
FIERCE PHARMA
Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD
03 Jul 2024 //
PRESS RELEASE
Kuehn Law Urges Regeneron Investors To Contact Firm
02 Jul 2024 //
PR NEWSWIRE
Odronextamab Recommended For EU Approval To Treat Lymphoma
28 Jun 2024 //
GLOBENEWSWIRE
Regeneron to Report Second Quarter 2024 Financial and Operating Results
27 Jun 2024 //
GLOBENEWSWIRE
Bayer`s pharmaceutical unit plans more managerial cuts in Europe, Asia
27 Jun 2024 //
REUTERS
US FDA approves Verona Pharma`s inhaled COPD therapy
27 Jun 2024 //
REUTERS
Dupixent® Positive Phase 3 Data in Children 1-11 with Eosinophilic Esophagitis
26 Jun 2024 //
GLOBENEWSWIRE
Arrowhead Axes Heart Disease Drug, Focuses on Another
26 Jun 2024 //
FIERCE BIOTECH
Intellia Shows Re-Dosing Possible for NTLA-2001
25 Jun 2024 //
FIERCE BIOTECH
Linvoseltamab Data Show Deepening Responses In Pretreated Myeloma
16 Jun 2024 //
GLOBENEWSWIRE
DiMe, Big Pharmas collab on framework for digital endpoints
12 Jun 2024 //
FIERCE BIOTECH
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active (pJIA)
11 Jun 2024 //
GLOBENEWSWIRE
Enforcement Report - Week of June 5, 2024
05 Jun 2024 //
FDA
FibroGen, Regeneron To Evaluate FG-3165, FG-3175 Plus LIBTAYO Combos
03 Jun 2024 //
GLOBENEWSWIRE
J&J acquires experimental skin disorder drug for $1.25 billion
29 May 2024 //
BIOPHARMADIVE
Regn7075 Egfr Costimulatory Combo: With Libtayo® Antitumor At Asco
23 May 2024 //
GLOBENEWSWIRE
ASCO: Regeneron misses mark with one CR in solid tumor trial
23 May 2024 //
FIERCE BIOTECH
Rezolute’s oral Eylea rival hits phase 2 goal, sending stock up
22 May 2024 //
FIERCE BIOTECH
Regeneron faces new biosimilar threats; an AI biotech lays off staff
22 May 2024 //
BIOPHARMADIVE
